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Abstract
AIM: To assess whether reasons for hepatitis C virus 
(HCV) therapy non-initiation differentially affect racial 
and ethnic minorities with human immunodeficiency 
virus (HIV)/HCV co-infection.
METHODS: Analysis included co-infected HCV treat-
ment-naïve patients in the University of North Carolina 
CFAR HIV Clinical Cohort (January 1, 2004 and December
31, 2011). Medical records were abstracted to document 
non-modifiable medical (e.g. , hepatic decompensation, 
advanced immunosuppression), potentially modifiable 
medical (e.g. , substance abuse, severe depression, 
psychiatric illness), and non-medical (e.g. , personal, 
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social, and economic factors) reasons for non-initiation. 
Statistical differences in the prevalence of reasons 
for non-treatment between racial/ethnic groups were 
assessed using the two-tailed Fisher’s exact test. Three 
separate regression models were fit for each reason 
category. Odds ratios and their 95%CIs (Wald’s) were 
computed.
RESULTS: One hundred and seventy-one patients 
with HIV/HCV co-infection within the cohort met study 
inclusion. The study sample was racially and ethnically 
diverse; most patients were African-American (74%), 
followed by Caucasian (19%), and Hispanic/other (7%). 
The median age was 46 years (interquartile range = 
39-50) and most patients were male (74%). Among the 
171 patients, reasons for non-treatment were common 
among all patients, regardless of race/ethnicity (50% 
with ≥ 1 non-modifiable medical reason, 66% with ≥ 
1 potentially modifiable medical reason, and 66% with 
≥ 1 non-medical reason). There were no significant 
differences by race/ethnicity. Compared to Caucasians, 
African-Americans did not have increased odds of non-
modifiable [adjusted odds ratio (aOR) = 1.47, 95%CI: 
0.57-3.80], potentially modifiable (aOR = 0.72, 95%CI: 
0.25-2.09) or non-medical (aOR = 0.90, 95%CI: 
0.32-2.52) reasons for non-initiation.
CONCLUSION: Race/ethnicity alone is not predictive 
of reasons for HCV therapy non-initiation. Targeted 
interventions are needed to improve access to therapy 
for all co-infected patients, including minorities.
Key words: Human immunodeficiency virus; Hepatitis C 
virus; Co-infection; Antiviral therapy; Race
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Core tip: Historically, hepatitis C virus (HCV) treat-
ment rates have been low in patients with human 
immunodeficiency virus (HIV) co-infection, especially 
for African-American patients. Identifying the reasons 
for treatment non-initiation may help improve treatment 
rates among racially and ethnic minorities. In our study 
of patients with HIV/HCV coinfection, non-modifiable 
medical reasons, potentially modifiable medical reasons, 
and non-medical reasons for non-treatment were 
common among all patients, regardless of their race/
ethnicity. There is a need to recognize and overcome 
potential treatment barriers in order to improve HCV 
treatment uptake in this patient population.
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INTRODUCTION
Hepatitis C virus (HCV) treatment rates have been 
low in patients who are co-infected with human immu-
nodeficiency virus (HIV). Up until 2011, when the 
first direct-acting antivirals (DAAs) became available, 
only one-third of co-infected patients were deemed 
eligible to receive HCV therapy, of whom less than one-
third initiated HCV treatment[1-4]. Of great concern is 
the proportion of racial and ethnic minorities with co-
infection that have not received HCV therapy. Nearly 
half of United States patients with HIV/HCV co-infection 
are African-American[5-7]. Previous studies involving 
older HCV regimens [pegylated interferon plus ribavirin 
(pegIFN-RBV)] reported that African-Americans were 
less likely than Caucasians to initiate HCV therapy[6,8,9]. 
Of co-infected patients in the HIV Outpatient Study 
during 1999-2007, African-Americans had a lower likeli-
hood of HCV treatment than Caucasians (HR = 0.3, 
95%CI: 0.2-0.6)[6]. African-American patients have been 
shown to not initiate therapy due to presence of IFN-
related contraindications or to defer therapy due to lack 
of symptoms[10,11]. 
Non-initiation of HCV therapy in co-infected patients 
is attributed to diverse factors such as patient- and 
provider-level barriers, perceived risks and benefits of 
therapy, and patient ineligibility to receive therapy due 
to medical contraindications[12]. Examples of medical 
conditions that sometimes precluded treatment with 
older regimens include hepatic decompensation, active
injection drug use (IDU), alcohol abuse, severe de-
pression, and advanced HIV-associated immunosuppre-
ssion[13-16].
Although these treatment-related barriers have 
been identified in the general co-infected population, 
scant research has documented their prevalence in co-
infected minorities. Some reasons for non-treatment, 
such as substance abuse, are potentially modifiable. 
Addressing them could help improve access to HCV 
therapy in minorities. Despite the clinical promise of 
the DAAs, it is possible that some of the historical 
challenges to treating patients with HIV/HCV co-
infection are still obstacles to treatment, particularly 
for minority patients[1,10,17]. The objectives of this study 
were to document reasons for non-treatment with HCV 
antiviral therapy and to assess how they differentially 
affect racial and ethnic minorities with HIV/HCV co-
infection.
MATERIALS AND METHODS
Study design and population
This was a retrospective study of patients with HIV/HCV 
co-infection enrolled in the University of North Carolina 
(UNC) Center for AIDS Research HIV Clinical Cohort. 
This prospective cohort began enrolling patients in 1996 
and includes over 4000 HIV-infected patients ≥ 18 
years of age who receive HIV care at UNC. The cohort, 
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approved by the UNC Institutional Review Board, has 
ongoing enrollment and participants provide written 
informed consent. Data for the cohort are retrieved from 
two sources. Patient demographic characteristics and 
laboratory values are retrieved electronically, whereas 
patient medication histories and comorbid conditions are 
obtained by standardized and comprehensive electronic 
medical record reviews. 
This study examined patients with HIV and HCV 
infection who had never received treatment for HCV 
and who had at least one outpatient clinic visit between 
January 1, 2004 and December 31, 2011. Patients 
were included in the study if they had the following: 
(1) a concomitant diagnosis of HCV based on positive 
HCV serostatus (as determined by HCV antibody 
test enzyme-linked immunosorbant assay/enzyme 
immunoassay); and (2) a positive HCV recombinant 
immunoblot assay (RIBA) test, detectable HCV RNA or 
HCV genotype test results. Patients with a history of 
HCV antiviral therapy were excluded. Anti-HCV therapy 
was defined as interferon, pegIFN, RBV, telaprevir, or 
boceprevir. The study period (2004-2011) was selected 
to best capture the timeframe when combination the-
rapy with pegIFN-RBV was the standard of treatment for 
most patients with co-infection.
Measurements
Baseline variables were retrieved from the cohort 
database and included patient demographics and clinical 
characteristics at time of HCV diagnosis. Baseline clinical 
characteristics were measurements taken proximal 
(allowing a 30-d window) to the date of the first positive 
HCV test. Demographic variables included age, gender, 
race/ethnicity (African-American, Caucasian, or Hispanic/
other), and insurance coverage (private, public, none, 
or other). Clinical characteristics included CD4, HIV-1 
RNA, HCV RNA, HCV genotype, HIV risk category (risk 
categories were not mutually exclusive), prior AIDS-
defining clinical conditions, and use of highly active 
antiretroviral therapy (HAART), defined as a combination 
of three or more antiretroviral drugs. Prior to May 1, 
2007, HCV RNA assays were measured in copies/mL, 
whereas subsequent HCV RNA assays were measured 
in IU/mL. Results for both assays are presented, where 
applicable, within the study period.
We reviewed individual medical records to identify 
reasons cited in the clinic notes by providers for not 
initiating HCV therapy. Reasons for treatment non-in-
itiation were then categorized as non-modifiable medical 
reasons, potentially modifiable medical reasons, or 
non-medical reasons. Non-modifiable medical reasons 
included death (patients with a poor life expectancy or 
patients that died before treatment was ever initiated), 
hepatic decompensation, advanced immunosuppression 
(CD4 < 200) not controlled by antiretroviral therapy, 
renal insufficiency, uncontrolled autoimmune conditions, 
or hematological disease. Potentially modifiable medical 
reasons included active or recent (within the past six 
months) IDU/cocaine use, alcohol use, severe depre-
ssion (defined as depression with suicidal ideation), 
psychiatric illness, or pregnancy/unwillingness to use 
contraception. Lastly, non-medical reasons included 
personal factors (e.g., refusal of available therapies, poor 
adherence to care), social factors (e.g., social instability, 
homelessness/lack of housing, lack of transportation), 
and economic factors (e.g., lack of health insurance, 
prohibitive cost).
Statistical analysis
Descriptive analyses were conducted on baseline 
variables, including demographic and clinical charac-
teristics. For each type of reason for non-treatment, the 
prevalence of the sub-categories by racial/ethnic groups 
was computed. Statistical differences in the prevalence 
of reasons for non-treatment between racial/ethnic 
groups were assessed using the two-tailed Fisher’s exact 
test. For each reason type (non-modifiable medical, 
potentially modifiable medical, and non-medical), risk 
factors such as age, gender, race/ethnicity, insurance 
status, and select HIV clinical characteristics were 
analyzed using multivariate logistic regression. Three 
separate regression models were fit for each reason 
type; the three reason types were the dependent 
variables in the respective models. Odds ratios and their 
95%CIs (Wald’s) were computed. All data analyses 
were conducted using SAS software (version 9.2; SAS 
Institute Inc., Cary, North Carolina, United States). All 
statistical analyses were performed by Lu Mao, a trained 
biostatistician with the UNC CFAR Biostatistics Core. 
RESULTS
Baseline demographics and clinical characteristics
Within the cohort, 246 patients had a positive HCV sero-
status and either a positive HCV RIBA test or detectable 
HCV RNA at baseline. Of these, 75 patients (30%) 
were excluded during the chart review process due to 
lack of HCV genotype results or due to reported history 
of antiviral therapy. We present results for the 171 
patients (70%) that met criteria for this study. Baseline 
demographic and clinical characteristics are summarized 
in Table 1. The median age was 46 years [interquartile 
range (IQR) = 39-50] and most patients were male 
(74%). The study sample was racially and ethnically 
diverse; most patients were African-American (74%), 
followed by Caucasian (19%), and Hispanic/other (7%). 
This largely reflects the racial/ethnic makeup of the 
clinical cohort. More than one-third of patients lacked 
any insurance coverage (37%).
At baseline, patients had a median (IQR) HIV-1 RNA 
of 4.3 (2.7-5) log10 copies/mL, a median (IQR) CD4 299 
(91-517) cells/μL, and 73% of patients were treated 
with HAART. Twenty-five patients (15%) had a baseline 
median (IQR) HCV RNA of 5.8 (5.7, 5.8) log10 copies/mL 
(values reported prior to May 1, 2007) and 10 patients 
(6%) had a baseline median (IQR) HCV RNA of 6.5 (6.2, 
6.7) log10 IU/mL (values reported after May 1, 2007). 
The most predominant HCV genotype was genotype 1 
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HIV-1 RNA, CD4, and prior AIDS-defining clinical con-
ditions as factors independently associated with reasons
for not initiating therapy (Table 3). Compared to Cau-
casian race/ethnicity, African-American race/ethnicity 
was not associated with having at least one non-modi-
fiable medical reason [adjusted odds ratio (aOR) = 
1.47, 95%CI: 0.57-3.80], potentially modifiable medical 
reason (aOR = 0.72, 95%CI: 0.25-2.09), or non-
medical reason (aOR = 0.90, 95%CI: 0.32-2.52).
DISCUSSION
While low uptake of older HCV antiviral regimens in 
HIV/HCV co-infected patients, particularly in racial and 
ethnic minorities, is well-documented in the literature, 
the reasons for low uptake are less clear[6,8,16]. This 
study evaluated reasons cited by the provider for 
non-initiation of HCV therapy in a cohort of untreated 
patients. Patients in our study were predominantly 
African-American and largely had genotype 1, which is 
comparable to other studies[1,18-21]. Our findings suggest 
that race/ethnicity alone is not predictive of having at 
least one reason for not initiating therapy. Rather, a key 
finding of this study was the high prevalence of multiple 
reasons for non-treatment, regardless of racial/ethnic 
group.
Nearly one-third of all patients in this study died 
without ever receiving HCV therapy. Of note, it cannot 
be assumed that patients who died would have ever 
initiated therapy while alive. Advanced immunosuppre-
ssion (CD4 < 200) was also a common reason for non-
treatment in our study. The majority (73%) of patients 
were on HAART at baseline, yet more than half of all 
patients had advanced immunosuppression documented 
as a reason for non-treatment, a finding that has been 
noted previously. In a study of patients with HIV/HCV 
co-infection at one of three Los Angeles HIV clinics, 
HAART use was common (> 90%), yet CD4 ≤ 200 was 
independently associated with decreased HCV treatment 
acceptance (OR = 0.08, 95%CI: 0.01-0.40)[13]. Treat-
ment guidelines suggest postponing HCV antiviral 
therapy in HIV/HCV co-infected patients with CD4 < 
200 and recommend HAART initiation to preserve and 
restore immune function[22]. Treatment-related factors 
such as adherence and regimen appropriateness can 
influence immune response. CD4 and HIV-1 RNA are 
indirect, objective measures of these treatment-related 
factors. However, we only evaluated baseline CD4 and 
HIV-1 RNA values, which precluded us from drawing 
inferences about the effects of adherence and regimen 
appropriateness on immunosuppression and resultant 
non-initiation of HCV therapy.
As expected, IDU/cocaine use was reported as a 
potentially modifiable reason for not initiating therapy. 
Past studies have classified substance abuse as an 
absolute contraindication to HCV therapy[23]. In a recent 
systematic review evaluating barriers to HCV therapy 
in HIV/HCV co-infected patients, substance abuse was 
(92%), followed by genotype 2 (5%), genotype 3 (3%), 
and genotype 4 (< 1%).
Documented reasons for HCV non-treatment
Reasons for HCV non-treatment did not vary signifi-
cantly by race/ethnicity (Table 2). Subcategories for 
each reason type are illustrated in Figure 1. At least 
one non-modifiable medical reason was documented 
in approximately half of all patients. Patient death was 
the most common non-modifiable medical reason in all 
three racial/ethnic groups, followed by advanced immuno-
suppression. Two-thirds of patients in each racial/ethnic 
group had at least one potentially modifiable reason for 
not initiating therapy (range 66%-69% across racial/
ethnic groups); of these, IDU/cocaine use and psychiatric 
illness was the most common, followed by alcohol use 
and severe depression. Non-medical reasons were also 
common in each racial/ethnic group; these were most 
often due to personal and social reasons, and least 
commonly due to economic reasons.
Factors associated with HCV non-treatment
We evaluated age, gender, race/ethnicity, insurance, 
Table 1  Baseline demographic and clinical characteristics of 
patients with human immunodeficiency virus/hepatitis C virus 
co-infection that did not initiate hepatitis C virus therapy
Variable Patients (n  = 171)
Patient demographics
Age (median, IQR)       46 (39, 50)
Male gender, n (%)  126 (73.7)
Race/ethnicity, n (%) -
   Caucasian    32 (18.7)
   African-American  126 (73.7)
   Hispanic/other  13 (7.6)
Insurance, n (%) -
   Private    23 (13.5)
   Public    67 (39.2)
   None    64 (37.4)
   Other  17 (9.9)
HIV clinical characteristics
   HIV-1 RNA (log10 copies/mL) (median, IQR)     4.3 (2.7, 5)
   CD4 (cells/μL) (median, IQR)       299 (91, 517)
   HAART, n (%)  125 (73.1)
   Prior AIDS-defining clinical condition, n (%)    37 (21.6)
HIV risk category, n (%)1 -
   MSM 41 (24)
   Injection drug use    97 (56.7)
HCV clinical characteristics
   HCV RNA log10 copies/mL (median, IQR)2        5.8 (5.7, 5.8)
   HCV RNA log10 (IU/mL) (median, IQR)3        6.5 (6.2, 6.7)
HCV genotype, n (%)4 -
   Genotype 1  157 (91.8)
   Genotype 2    8 (4.7)
   Genotype 3    6 (3.5)
   Genotype 4    1 (0.6)
1HIV risk categories were not mutually exclusive; 2n = 25 patients with 
RNA reported as copies/mL (prior to May 1, 2007); 3n = 10 patients with 
RNA reported as IU/mL (following to May 1, 2007); 4Genotypes 1 and 2 
were both reported in one patient. IQR: Interquartile range; HIV: Human 
immuno-deficiency virus; HCV: Hepatitis C virus; HAART: Highly active 
antiretroviral therapy; MSM: Men who have sex with men.
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the most frequently cited barrier[23]. However, substance 
users should not be routinely excluded from treatment, 
as substance use can fluctuate with time[24]. Recent 
guidelines recommend deferral of treatment if active 
or ongoing substance abuse is expected to interfere 
with regimen adherence, and frequent re-evaluation of 
each patient’s adherence to routine medical care, other 
comorbidities, and potential for reinfection[15,24].
Personal and social factors were commonly reported 
in all racial/ethnic groups as reasons for not initiating 
therapy. Engagement in care and adherence are often 
perceived by the provider as an indicator of treatment 
readiness and are based on characteristics such as 
mental health, clinic attendance, substance use, and the 
patient’s attitudes and beliefs about therapy[25]. These 
factors can decrease the likelihood of patient referral for 
HCV care.
Historically, patients with HIV/HCV, most often 
African-Americans, have had poor virologic response to 
HCV therapy[26-29]. African-Americans have been shown 
to be less likely to accept pegIFN-RBV antiviral therapy 
when it was recommended by their providers[13]. It 
has been suggested that patient awareness of low 
sustained virologic response (SVR) among African-
Americans with genotype 1 may contribute to decisions 
to refuse therapy[11]. The high proportion of personal 
factors for non-treatment in our study could have also 
been attributed to patient refusal of pegIFN-RBV in 
anticipation of more effective, and ultimately more 
convenient, therapies. DAA-based therapy demonstrates 
excellent efficacy in clinical trials; 87% SVR has been 
attained in African-Americans[30]. Nevertheless, some of 
the reasons for non-treatment identified in the present 
study are still likely barriers to the DAAs. 
Current treatment guidelines acknowledge substance 
abuse, psychiatric disorders, and lack of access (e.g., 
cost, insurance, distance to provider) as barriers to 
current HCV treatment regimens that include DAAs[31]. 
Several strategies are proposed to increase HCV 
treatment, particularly DAA therapy, in patients with 
HIV/HCV. At the patient level, pre-treatment educa-
tion, management of comorbidities and mental health 
conditions, and harm reduction counseling in individu-
als with continued substance abuse can be provided 
through patient referral for specialty services, such as 
substance abuse treatment and psychiatric therapy[24]. 
Strategies at the provider level include collaborative 
care models with primary care providers and HCV 
specialists[32], and co-localization models that combine 
HCV treatment and care with other primary medical care 
or substance abuse treatment and social services[31]. 
Systems-level strategies are needed, such as medication 
patient assistance programs, removal of Medicaid state 
restrictions regarding substance abuse and HCV therapy, 
Table 2  Prevalence of reasons for hepatitis C virus non-treatment in patients with human immunodeficiency virus/hepatitis C virus 
co-infection
Total Race/ethnicity
(n  = 171) African-American 
(n  = 126)
Caucasian 
(n  = 32)
Hispanic/other 
(n  = 13)
P  value1
≥ 1 non-modifiable medical reason, n (%)   85 (49.7) 64 (50.8) 14 (43.8) 7 (53.8) 0.806
≥ 1 potentially modifiable medical reason, n (%) 113 (66.1) 83 (65.9) 21 (65.6) 9 (69.2) 1.000
≥ 1 non-medical reason, n (%) 113 (66.1) 85 (67.5) 21 (65.6) 7 (53.8) 0.597
1Fisher’s exact test.
Table 3  Multivariate analyses for associations between characteristics and reasons for hepatitis C virus non-treatment
Variable Non-modifiable medical reason Potentially modifiable medical reason Non-medical reason
aOR (95%CI) aOR (95%CI)  aOR (95%CI)
Age (yr) 1.00 (0.96-1.05) 0.93 (0.87-0.98) 0.99 (0.94-1.04)
Gender
   Female Ref Ref Ref
   Male 1.07 (0.47-2.43) 0.77 (0.30-1.95) 1.57 (0.66-3.71)
Race/ethnicity
   Caucasian Ref Ref Ref
   African-American 1.47 (0.57-3.80) 0.72 (0.25-2.09) 0.90 (0.32-2.52)
   Hispanic/other   1.94 (0.34-11.18)   1.65 (0.14-18.83) 0.46 (0.08-2.88)
Insurance
   Private Ref Ref Ref
   Public 1.30 (0.39-4.27) 2.27 (0.65-7.93) 0.69 (0.15-3.10)
   None 0.64 (0.19-2.05) 1.13 (0.34-3.76) 0.44 (0.13-1.56)
   Other 0.82 (0.32-3.13) 3.03 (0.59-15.6) 0.50 (0.09-2.68)
HIV-1 RNA log10 1.08 (0.79-1.49) 0.95 (0.67-1.34) 1.11 (0.80-1.56)
CD4 0.99 (0.99-1.00) 1.00 (0.99-1.00) 0.99 (0.99-1.00)
Prior AIDS-defining clinical condition 0.46 (0.09-2.37) 0.58 (0.10-3.28)   1.49 (0.15-14.65)
aOR: Adjusted odds ratio; HIV: Human immuno-deficiency virus; AIDS: Acquired immune deficiency syndrome.
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decrease prescription prior authorization requirements, 
and ultimately, to lower DAA drug prices in order to 
increase treatment access for patients[33].
Our study is subject to limitations. The UNC clinic is 
a large academic center and may not be representative 
of patients receiving care in other clinic settings. All 
baseline variables were retrieved from the clinical cohort 
database; however, individual patient records were 
reviewed to ascertain reasons for non-treatment in the 
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Figure 1  Documented reasons for hepatitis C virus non-treatment in patients with human immunodeficiency virus/hepatitis C virus coinfection patients, 
by race/ethnicity. Patients may have had more than one reason for non-treatment.
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collection include variability in documentation across 
clinic providers, missing data due to errors that occur 
during clinic visit narrative dictation and transcription, 
and lack of specificity for patient information. Listed 
reasons were based on providers’ cited reasons for not 
initiating HCV therapy. These may differ from patient-
reported barriers to care that are specific to racial and 
ethnic groups, such as medical mistrust[34]. As our study 
was designed to focus on the untreated, we were unable 
to make any causal associations between documented 
reasons and why patients were not treated. We did 
not assess continuity of HAART. Given that advanced 
immunosuppression greatly contributed to having a non-
modifiable medical reason, it is possible that patients 
who had advanced immunosuppression documented as 
a reason for non-treatment were maintained on HAART, 
but did not experience the full clinical benefits of HAART 
due to regimen adherence, regimen appropriateness, 
and/or due to inability for some patients to achieve 
immune reconstitution[35]. We did not measure these 
factors in our study. Lastly, we did not evaluate diffe-
rences in HCV treatment by race/ethnicity, and were 
therefore, unable to determine if any treatment dispari-
ties exist among patients in the UNC clinic.
In summary, reasons for non-treatment did not diffe-
rentially affect racial and ethnic minorities co-infected 
with HIV/HCV. Rather, there was a high prevalence of 
multiple reasons for non-treatment in patients, regard-
less of racial/ethnic group. The advent of DAAs has 
undoubtedly revolutionized HCV care, however, there 
is still a need to recognize and overcome potential treat-
ment barriers in order to improve treatment uptake and 
eradicate HCV in this patient population.
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having at least one reason for not initiating therapy. Rather, a key finding of this 
study was the high prevalence of multiple reasons for non-treatment, regardless 
of racial/ethnic group.
Innovations and breakthroughs
While low uptake of older HCV antiviral regimens in HIV/HCV co-infected 
patients, particularly in racial and ethnic minorities, is well documented in 
the literature, the reasons for low uptake are less clear. This study evaluated 
reasons cited by the provider for non-initiation of HCV therapy in a cohort of 
untreated patients.
Applications
This study demonstrates that there is a need to recognize and overcome 
potential treatment barriers in order to improve HCV treatment uptake in this 
patient population.
Peer-review
This article is of interest to clinicians that manage patients with HIV/HCV 
coinfection.
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